Warts refer to non-cancerous skin growths that can appear as small lumps on the genitals, face, hands, and feet. It is caused by viruses called human papillomaviruses (HPV). Warts are prevalent among children and teenagers, with various studies suggesting that nearly 33% of this population is affected by warts. Thus, the increasing cases and high recurrence rates of warts are augmenting the demand for more effective and long-lasting wart treatments.
Major companies involved in the warts pipeline drugs market include Merck Sharp & Dohme LLC and Nielsen BioSciences, Inc., among others.
Leading drugs currently under the pipeline include Candin, 2LVERU®, and 2LVERU® JUNIOR, among others.
Increasing cases of HPV infections (the primary cause of warts) and the growing awareness about skin conditions are poised to positively influence the warts pipeline landscape in the coming years.
The Warts Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into warts therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Warts. The warts report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The warts pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with warts treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing warts pipeline development activities.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Warts are small, fleshy growths that can develop on the skin and inside the mouth. They can differ in appearance and are often round, flat, or smooth. Various strains of human papillomavirus (HPV) can cause warts. Common warts, plantar warts, flat warts, and genital warts are some of the types of warts.
Treatment primarily focuses on removing warts, preventing recurrence, and addressing underlying HPV infections. Salicylic acid, available in the form of over-the-counter (OTC) gels, patches, or solutions, is commonly used as a topical treatment in mild cases. Other warts therapeutics include immunotherapy such as Candida antigen or interferon to stimulate the immune system to target the wart. Further, the growing focus on gene-based therapies and therapeutic vaccines is anticipated to support pipeline expansion in the near future.
Warts are a common medical condition, affecting around 10% of the population . It can occur at any age, with a high prevalence found among school-aged children. However, it is rare in infancy and early childhood.
Both men and women are almost equally affected by warts. In Whites, the condition is more common compared to Blacks or Asians. Warts are also prevalent among immunosuppressed people and meat handlers.
This section of the report covers the analysis of warts drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
EMR’s warts report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s Warts report assessment covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with a substantial number of warts emerging drugs undergoing clinical development.
The drug molecule categories covered under warts pipeline analysis include small molecules, biologics, nucleic acid-based molecules, natural extracts and phytochemicals, peptides-based molecules, and others. The warts report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for warts.
The EMR report for the warts drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed warts therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in warts clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for warts. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of warts drug candidates.
Sponsored by Nielsen BioSciences, Inc., the objective of this randomized, double-blinded, clinical trial is to investigate the efficacy and safety of candin for the treatment of Verruca Vulgaris (common warts) in adolescents and adults. The study is under Phase III clinical development and has an estimated 330 participants.
Labo'Life is conducting a Phase IV placebo-controlled, double-blind study aimed at examining the efficacy and safety of Warts drug candidates 2LVERU® JUNIOR and 2LVERU®. The interventional study has enrolled about 162 patients and is expected to be completed by March 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Warts Pipeline Insights provides a strategic overview of the latest and future landscape of treatments for warts. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities provided by warts drug report.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share